Sarcoma | Clinical

January 25, 2023

Matthew Ingham, MD, discusses some of the most recent clinical updates in the sarcoma space.

January 12, 2023

A phase 1 trial showed efficacy of a novel T-cell therapy targeting MAGE-A4 in solid tumors, particularly synovial sarcoma.

November 23, 2022

Investigators in the IT-01 trial of INT230-6 as monotherapy or combined with ipilimumab showed safety and potential efficacy in patients with sarcoma.

November 22, 2022

With an overall response rate of 38.6% and a consistent safety profile of that seen in prior trials, afamitresgene autoleucel continues to show clinical responses in patients with late-stage synovial sarcoma.

November 21, 2022

Matthew Ingham, MD, discusses understanding the genomics of sarcomas and how molecular testing can be useful in this space.

November 17, 2022

Fifty percent of patients with advanced soft tissue sarcoma enrolled in the phase 1b study of camsirubicin and pegfilgrastim had stable disease.

October 24, 2022

Matthew Ingham, MD, discusses the unique biology of uterine sarcomas.

October 20, 2022

A suspected unexpected serious adverse reaction to seclidemstat led the developer to pause a phase 1/2 evaluating the agent in patients with Ewing and FET-rearranged sarcoma.

October 11, 2022

Twelve-week safety data from the phase 2 ENVASARC trial of envafolimab alone and in combination with ipilimumab in patients with undifferentiated pleomorphic sarcoma and myxofibrosarcoma support proceeding with enrollment of patients in the trial.

September 13, 2022

The FDA has granted an orphan drug designation to DUNP19 for patients with osteosarcoma.